ISPE 2025
August 22 - 26, 2025 | Washington, DC, USA
Gold Sponsor
August 2025
Carelon Research is a proud sponsor of ISPE 2025. Visit us in person at booth #400. Connect with our experts and see our latest research.
SKILLS COURSE
Friday, August 22, 2025
9:00 AM – 12:30 PM
Session: Pre-Conference Skills Course
Location: Room 202 AB
Using pharmacoepidemiology database resources to address drug safety research
SC-05 | An overview of the various approaches available to conduct validation studies. The presentation will focus on the mechanics of medical record validation studies and the impact on bias analyses within pharmacoepidemiology studies.
Daniel C. Beachler, PhD, MHS
Staff Vice President, Safety and Epidemiology
Topic: Data validation approaches in pharmacoepidemiology {30 minutes}
Haynes, K1, Gini R2, Reynolds M3, Beachler DC4, Raman SR5
1Johnson & Johnson, Horsham, USA, 2ARS Toscana, Florence, Italy, 3 Flatiron Health, Grasonville, MD, USA, 4Carelon Research, Wilmington, DE, USA, 5Duke University School of Medicine, Durham, NC, USA
Carelon Research presentations
Carelon Research authors are indicated in bold.
*Associate at time of study.
|
Presentation |
Session |
Title |
Authors |
Affiliations |
|---|---|---|---|---|
|
Podium Sunday, August 24, 2025 Room 208 AB |
1D - Pharmacovigilance/Cardiovascular |
[1D-02] Risk of Incident Supraventricular Tachycardia Following Exposure to Recombinant Zoster Vaccine in Adults >50 Years of Age in the United States |
Mayer SE[1], Alam S[1], Peters A[1], Messenger-Jones E[1], Li D[1], Platt R[1], Suleiman B[2], Granger CB[2], Moyneur E[3], Ma Q[4], Selvan M[4], Ogilvie RP[5], Ziyadeh NJ[5], Daniels K[6], Wentz AE[6], Djibo DA[7], McMahill-Walraven CN[8], Oraichi D[9], Seifert H[9], Franck V[10], Yun H[9], Spence O[9], Kluberg SA[1] |
[1] Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Durham, NC, USA, [2] Duke University Health, Durham, NC, USA, [3] StatLog, Montreal, Quebec, Canada, [4] Humana Healthcare Research, Louisville, KY, USA, [5] Optum, Eden Prairie, MN, USA, [6] Carelon Research, Wilmington, DE, USA, [7] CVS Health, Philadelphia, PA, USA [8] Glade Oak Inc., Royersford, PA, USA [9] GSK, Philadelphia, PA, USA, [10] GSK, Warve, Wallon Region, Belgium |
|
Podium Sunday, August 24, 2025 Room 208 AB |
1D - Vaccines |
[1D-05] Rapid Surveillance Study to Evaluate Safety of Respiratory Syncytial Virus (RSV) Vaccine (ABRYSVOTM) Exposure During Pregnancy in the United States |
MacDonald SC[1], Gandhi S[2], Adimadhyam S[3], Albert S[3], Anastasiou O[4], Andrade SE[3], Back S[3], Cosgrove A[3], Djibo DA[5], Loram N[1], Kuntz JL[6], Lino MM[7], Love SAM[8], McElroy NP[3], McMahill-Walraven CND[9], Michnick AI[3], Palmsten K[10], Petrone AB[3], Platt R[3], Round KE[3], Rubino H[2], Wentz AE[8], Zhang F[3], Maro JC[3] |
[1] Pfizer Inc., Orangeville, Ontario, Canada, [2] Pfizer Inc., Warren, NJ USA, [3] Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA, [4] Pfizer Inc., Athens, Greece, [5] CVS Health, Philadelphia, PA, USA, [6] Kaiser Permanente Center for Health Research, Portland, OR, USA, [7] Pfizer, Inc., Roma, Italy, [8] Carelon Research, Wilmington, DE, USA, [9] Glade Oak Inc., Royersford, PA, USA, [10] HealthPartners Institute, Bloomington, MN, USA |
|
Podium Sunday, August 24, 2025 Room 207 AB |
2C - Vaccines |
[2C-06] Analyzing Incidence of Adverse Events Commonly Assessed in Vaccine Safety Studies in Medicaid versus Commercially-Insured Populations in Carelon Research’s OMOP Data |
Parlett LE[1], Avula R[1], Beachler DC[1], Stockbower G[1], Secora A[2], Thelus R[2] |
[1] Carelon Research, Wilmington, DE, USA, [2] IQVIA, Falls Church, VA, USA |
|
Podium Monday, August 25, 2025 Room 206 |
4C - Drug Utilization Research/Trends and comparisons |
[4C-06] Evolution of Drug Initiation Patterns and Clinical Characteristics of New Users of Dapagliflozin in the United States up to 10 Years after Approval to Treat Type 2 Diabetes |
Danysh HE[1], Khan AM[1], Daniels K[2], Gilsenan A[1], Beachler DC[2], Bartsch J[1], Quimbo T[2], Garbinsky D[1], Calingaert B[1], Abibula W[3], Gutierrez L[1] |
[1] RTI Health Solutions, Waltham, MA, USA, [2] Carelon Research, Wilmington, DE, USA, [3] AstraZeneca, Mississauga, Ontario, Canada |
|
Podium Tuesday, August 26, 2025 Room 204 AB |
5C-Covid-19 Vaccine Safety: Science, Facts, and Public Health Vaccines |
[5C-02] Quantitative Bias Analysis to Assess Impact of Outcome Misclassification in a Claims-based COVID-19 Vaccine Safety Study in the US |
Mayer SE[1], Layton JB[2], Praet N[3], Haynes K[4], Alam S[1], Bell EJ[1], Brown JS[5], Coughlin K[1], Daniels K[6], Dea K[7], DeVries A[8], Diessner B[9], Djibo DA[10], Horgan C[1], Love SAM[6], Ma Q[8], McMahill-Walraven CN[11], Moyneur E[7], Platt R[1], Reynolds JS[1], Selvan M[8], Yost E[4], Zhao Y[10], Ziyadeh NJ[9], Fuller CC[1], Gilsenan A[2] |
[[1] Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Durham, NC, USA, [2] RTI Health Solutions Triangle Park, NC, USA, [3] Johnson & Johnson, Beerse, Belgium, [4] Johnson & Johnson, Horsham, PA, USA, [5] TriNetX, Needham, MA, USA [6] Carelon Research, Wilmington, DE, USA, [7] StatLog, Montreal, Quebec, Canada, [8] Humana Healthcare Research, Louisville, KY, USA [9] Optum, Boston, MA, USA, [10] CVS Health, Philadelphia, PA, USA, [11] Glade Oak Inc., Royersford, PA, USA, [12] |
|
Podium Tuesday, August 26, 2025 Room 204 AB |
5C-Covid-19 Vaccine Safety: Science, Facts, and Public Health Vaccines |
[5C-04] An Observational Postauthorization Safety Study to Assess Adverse Events of Special Interest in Recipients of Ad26.COV2.S in the United States |
Layton JB[1], Mayer SE[2], Praet N[3], Haynes K[4], Alam S[2], Brown JS[5], Calingaert B[1], Daniels K[6], Dea K[7], DeVries A[8], Diessner B[9], Djibo DA[10], Hague JC[2], Horgan C[2], Hugh C[2], Johannes CB[1], Ko JS[2], Love SAM[6], Ma Q[8], McMahill-Walraven CN[11], Moyneur E[7], Platt R[2], Selvan M[8], Wang X[10], Yost E[4], Ziyadeh NJ[9], Fuller CC[2], Gilsenan A[1] |
[1]US Food and Drug Administration, Silver Spring, MD, [2]Acumen LLC, Burlingame, CA, USA, [3]Optum Epidemiology, Boston, MA, USA, [4]Carelon Research, Wilmington, DE, USA, [5]CVS Health, Blue Bell, PA, USA, [6]United Health, Boston, MA, USA, [7]IQVIA, Falls Church, VA, USA |
|
Podium Tuesday, August 26, 2025 Room 202 AB |
5E - Safety Outcomes/Neurological/Mental Health |
[5E-04] Comparative safety of glucagon-like peptide 1 receptor agonists (GLP-1-RAs) in chronic weight management patients without diabetes: a real-world data study |
Hoffman SR[1], Lanes S[1], Quimbo T[1], Papazian A[1], White J[2], Fisher V[2], Cziraky M[1], Crowley M[3], Willey V[1] |
[1] Carelon Research, Wilmington, DE, USA, [2] CarelonRX, Morristown, NJ, USA, [3] Duke University Medical Center, Durham, NC, USA |
|
Podium Tuesday, August 26, 2025 Room 201 |
5G –Environmental Pharmacoepidemiology |
[5G-05] The impact of extreme heat on mental health utilization and prescription use |
Romine J[1], Liu A[1], Cullen D[2], Tang K[2], Talavera M[2], Nazarian A[2], Mattson H[2], Schrager N[1], Chi W[1] |
[1] Carelon Research, Wilmington, DE, USA, [2] Elevance Health, Indianapolis, IN, USA |
|
Podium Tuesday, August 26, 2025 Room 204 AB |
5C-Covid-19 Vaccine Safety: Science, Facts, and Public Health Vaccines |
[5C-06] Incidence Rates of Myocarditis/Pericarditis after Pfizer-BioNTech COVID-19 Vaccine in the United States: Interim Results From a Postapproval Safety Study, Primary Series Analysis |
Fuller CC[1], Kawai A[2], Hawrusik R[1], Koram N[3], Agan AA[1], Avula R[4], Brown JS[5], Burk J[1], Calingaert B[2], Chomistek AK[6], Connolly JG[1], Daniels K[4], Dea K[7], DeFor TA[8], DeVries A[9], Diessner B[6], Djibo DA[10], Ezzy SM[6], Johannes CB[2], Cai B[3], Layton JB[2], Love SAM[4], Mayer SE[1], Ma Q[9], Moyneur E[7], Nolan MB[8], Rao S[2], Reynolds JS[1], Selvan M[9], Sharma V[10], McMahill-Walraven CN[11], Vetter J[6], Ziyadeh NJ[6], Gilsenan A[2], Platt R[1] |
[1] Harvard Pilgrim Health Care Institute, Boston, MA, USA, [2] RTI Health Solutions, Waltham, MA, USA, [3] Pfizer, Inc., Warren, NJ, USA, [4] Carelon Research, Wilmington, DE, USA, [5] TriNetX, Needham, MA, USA, [6] Optum, Boston, MA, USA, [7] StatLog, Montreal, Quebec, Canada, [8] HealthPartners Institute, Bloomington, MN, USA, [9] Humana Healthcare Research, Louisville, KY, USA, [10] CVS Health, Philadelphia, PA, USA, [11] Glade Oak Inc., Royersford, PA, USA |
|
Podium Tuesday, August 26, 2025 Ballroom AB |
6E – One size fits none: unravelling treatment heterogeneity Methods in Pharmacoepidemiology/Analytical Methods |
[6E-01] Calculating number needed to treat (NNT) for studies using real world data with variable follow-up times: Kaplan-Meier versus rate-based approach |
Hoffman SR[1], Lanes S[1], Quimbo T[1], Papazian A[1], White J[2], Fisher V[2], Cziraky M[1], Crowley M[3], Willey V[1] |
[1] Carelon Research, Wilmington, DE, USA, [2] CarelonRX, Morristown, NJ, USA, [3] Duke University Medical Center, Durham, NC, USA |
|
Podium Tuesday, August 26, 2025 Room 201 |
6D – Disease Epidemiology / Clinical Course / Cancer |
[6D-02] Developing a Cancer Stage Model in Patients with Incident Colorectal Cancer Using Data from a Cancer Care Quality Program and Administrative Claims |
Haley V[1], Van Rompay MI[1], Smith JL *[1], Chaudhary S[1], Schott K[1], Mack M[1], Vojjala SK[1], Parlett LE[1] |
[1] Carelon Research, Wilmington, DE, USA |
|
Podium Tuesday, August 26, 2025 Room 201
|
6D – Lightning Session 3 Health Equity |
[6D-08] Whose Health is Impacted by Income Inequality? Associations Between County-Level Income Inequality and Pharmacy Spending in an Insured Population |
Johnson M[1], Chi W[1], Silver C[1], Agrawal S[2], Gray D[2] |
[1] Carelon Research, Wilmington, DE, USA, [2] Elevance Health, Indianapolis, IN, USA |
|
Presentation |
Session |
Title |
Authors |
Affiliations |
|---|---|---|---|---|
|
Poster Sunday, August 24, 2025 Convention Hall |
Poster Session A: Benefit-Risk Assessment, Communication, and Evaluation (BRACE) |
[A-019] Patients’ and Caregivers' Understanding of the Serious Risks of Opioid Analgesics and How to Use These Products Safely: A Patient/Caregiver Survey |
Wentz AE[1], Zeremski M[2], Stephenson JJ[1], Hopkins K[1] |
[1] Carelon Research, Wilmington, DE, USA, [2] Clinical Directors Network, New York, NY, USA |
|
Poster Sunday, August 24, 2025 Convention Hall |
Poster Session A: Safety Outcomes / Diabetes |
[A-313] Post-authorization Safety Study to Assess the Risk of Diabetic Ketoacidosis among Type 2 Diabetes Mellitus Patients Treated with Ertugliflozin Compared to Patients Treated with Other Antihyperglycemic Agents |
Rai A[1], Marshall J[1], Nandyala S[1], Her M[1], Agan AA[1], Huang TY[2], Rodriguez-Watson C[3], Clary A[4], Diessner MB[5], Nolan M[6], Djibo DA[7], DeVries A[8], Daniels K[9], Zhang X[10], Wang T[10], Gantz I[10], Shankar R[10], Zale MM[10], Ejelonu P[10], Toh S[1] |
[1] Harvard Pilgrim Health Care Institute, Boston, MA, USA, [2] Komodo Health, New York, NY, USA, [3] Regan-Udall Foundation, Washington, DC, USA, [4] Evidence to Practice, Washington, DC, USA, [5] Optum, Boston, MA, USA [6] HealthPartners Institute, Bloomington, MN, [7] CVS Health, Woonsocket, RI, USA, [8] Humana Healthcare Research, Louisville, KY, USA, [9] Carelon Research, Wilmington, DE, USA, [10] Merck & Co., Inc., Rahway, NJ, USA |
|
Poster Sunday, August 24, 2025 Convention Hall |
Poster Session A: Vaccines |
[A-329] Safety Monitoring of Health Outcomes following Influenza Vaccination during the 2023-2024 Season among U.S. individuals aged 6 months through 64 years |
Lloyd PC[1], Achara G[2], Zhao H[2], Chen B[2], Beachler DC[3], Secora A[4], Amend KL[5], Djibo DA[6], Ambarsoomzadeh D[2], Lyu B[2], Clark TC[1], Ng X[1], Parlett LE[3], Thelus R[4], Wilkinson M[5], Parambi RJ[5], Song J[5], Stone A[5], Tarazi W[5], Ding N[5], Yang GW[5], Wang X[6], McMahill-Walraven CN[7], Hu M[2], Chillarige Y[2], Forshee RA[1], Anderson SA[1] |
[1] FDA, Silver Spring, MD, USA, [2], Acumen, Burlingame, CA, USA, [3] Carelon Research, Wilmington, DE, USA, [4] IQVIA, Falls Church, VA, USA [5] Optum, Boston, MA, USA [6] CVS Health, Philadelphia, PA, USA [7] Glade Oak Inc., Royersford, PA, USA |
|
Poster Sunday, August 24, 2025 Convention Hall |
Poster Session A: Vaccines |
[A-333] Incidence Rates of Safety Events of Interest in a Post-Approval Study of Pfizer-BioNTech Original Monovalent COVID-19 Vaccine in the United States: Primary Series Analysis |
Kawai A[1], Fuller CC[2], Koram N[3], Agan AA[1], Brown JS[4], Burk J[2], Cai B[3], Calingaert B[1], Chomistek AK[5], Connolly JG[2], Daniels K[6], Dea K[7], DeVries A[8], Diessner B[5], Djibo DA[9], Ezzy SM[5], Hawrusik R[2], Johannes CB[1], Layton JB[1], Love SAM[6], Ma Q[8], Mayer SE[2], McMahill-Walraven[10], Moyneur E[7], Nolan MB[11], Rao S[1], Reynolds JS[2], Selvan M[8], Vetter J[5], Wang X[9], Wideman K[1], Ziyadeh NJ[5], Platt R[2], Gilsenan A[1] |
[1] RTI Health Solutions, NC, USA, [2] Harvard Pilgrim Health Care Institute, Boston, MA, USA, [3] Pfizer Inc., Warren, NJ, USA, [4] TriNetX, Needham, MA, USA, [5] Optum, Boston, MA, USA, [6] Carelon Research, Wilmington, DE, USA, [7] StatLog, Montreal, Quebec, Canada, [8] Humana Healthcare Research, Louisville, KY, USA, [9] CVS Health, Philadelphia, PA, USA, [10] Glade Oak Inc., Royersford, PA, USA, [11] HealthPartners Institute, Bloomington, MN, USA |
|
Poster Sunday, August 24, 2025 Convention Hall |
Poster Session A: Vaccines |
[A-334] Incidence rates of safety outcomes in a post-approval study of the Pfizer-BioNTech monovalent COVID-19 vaccine in the United States, booster dose analysis |
Hawrusik R[1], Kawai A[2], Agan AA[1], Koram N[3], Avula R[4], Brown JS[5], Burk J[1], Cai G[3], Calingaert B[2], Chomistek AK[6], Connolly JG[1], Daniels K[4], Dea K[7], DeFor TA[8], DeVries A[9], Diessner B[6], Djibo DA[10], Ezzy SM[6], Johannes CB[2], Layton JB[2], Love SAM[4], Mayer SE[1], Ma Q[9], Moyneur E[7], Nolan MB[8], Platt R[1], Rao S[2], Reynolds JS[1], Selvan M[9], Sharma V[10], McMahill-Walraven CN[11], Vetter J[6], Ziyadeh N[6], Gilsenan A[2], Fuller CC[2] |
[1] Harvard Pilgrim Health Care Institute, Boston, MA, USA, [2] RTI Health Solutions, Research Triangle Park, NC, USA, [3] Pfizer Inc., Warren, NJ, USA, [4] Carelon Research, Wilmington, DE, USA, [5] TriNetX, Needham, MA, USA, [6] Optum, Boston, MA, USA, [7] StatLog, Montreal, Quebec, Canada, [8] HealthPartners Institute, Bloomington, MN, USA, [9] Humana Healthcare Research, Louisville, KY, USA, [10] CVS Health, Philadelphia, PA, USA, [11]Glade Oak Inc., Royersford, PA, USA |
|
Poster Sunday, August 24, 2025 Convention Hall |
Poster Session A: Vaccines |
[A-350] Baseline Characteristics of Patients Included in a Post-Approval Safety Study of Pfizer-BioNTech Monovalent COVID-19 Vaccine in the United States: Results from an Interim Analysis |
Rao S[1], Fuller CC[2], Koram N[3], Agan AA[2], Brown JS[4], Burk J[2], Cai B[3], Calingaert B[1], Chomistek AK[5], Connolly JG[2], Daniels K[6], Dea K[7], DeVries A[8], Diessner B[5], Djibo DA[9], Ezzy SM[5], Hawrusik R[2], Johannes CB[1], Kawai A[1], Layton JB[1], Love SAM[6], Ma Q[8], Mayer SE[2], McMahill-Walraven CN[10], Moyneur E[7], Nolan MB[11], Reynolds JS[2], Selvan M[8], Vetter J[5], Wang X[9], Widemann K[1], Zhao Y[9], Ziyadeh NJ[5], Platt R[2], Gilsenan A[1] |
[1] RTI Health Solutions, NC, USA, [2] Harvard Pilgrim Health Care Institute, Boston, MA, USA, [3] Pfizer Inc., Warren, NJ, USA, [4] TrinetX, Needham, MA, USA, [5] Optum, Boston, MA, USA, [6] Carelon Research, Wilmington, DE, USA, [7] StatLog, Montreal, Quebec, Canada, [8] Humana Healthcare Research, Louisville, KY, USA, [9] CVS Health, Philadelphia, PA, USA, [10] Glade Oak Inc., Royersford, PA, USA, [11] HealthPartners Institute, Bloomington, MN, USA |
|
Poster Sunday, August 24, 2025 Convention Hall |
SPOTLIGHT |
[SLA-033] Integration of Two Large Databases for an Observational Cohort Study of Exposure to Galcanezumab during Pregnancy among Women with Migraine |
Adaji E[1], Mawanda F[1], Schroeder K[1], Hoffman SR[2], Coley B[2], Schott K[2], Dudman D[2], Lanes S[2] |
[1] Eli Lilly and Company, Indianapolis, IN, USA, [2] Carelon Research, Wilmington, DE, USA |
|
Poster Monday, August 25, 2025 Convention Hall |
Poster Session B: Drug Utilization Research / Changing drug utilization (intervention and implementation research) |
[B-046] Trends over time in antidiabetic medication use under age 65 in the United States: impact of obesity treatment |
Daniels K[1], Quimbo T[1], Danysh HE[2], Gutierrez L[2], Beachler DC[1] |
[1] Carelon Research, Wilmington, DE, USA, [2] RTI Health Solutions, Waltham, MA, USA |
|
Poster Monday, August 25, 2025 Convention Hall |
Poster Session B: Methods in Pharmacoepidemiology / Measurement Methods |
[B-224] Towards Optimizing Identification of First Line of Therapy (LOT) for Metastatic Lung, Breast and Colorectal Cancer in Real World Data: A Scoping Review |
Onasanya O[1], Mahmoudpour H[2], Bates B[3], Shui I[4], Liu G[5], Tan EH[6], Yang YH[7], Salas M[8], Fadare J[9], Bennett D[10], de Miranda Drummond PL[11], Shin JY[12], Guleria S[13], Wang JR[14], Hada M[15], Denis H[16], Setoguchi S[3], Truter I[17], Lopes LC[18], Dixon R[1] |
[1] Carelon Research, Wilmington, DE, USA, [2] Merck Healthcare, Germany, [3] Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ, USA, [4] Merck & Co., NJ, USA, [5] University of Toronto, Toronto, Canada, [6] University of Oxford, United Kingdom, [7] National Health Research Institutes, Zhunan Town, Miaoli County 350, Taiwan, [8] Bayer Pharmaceuticals, Whippany, NJ, USA, [9] Ekiti State University, Nigeria, [10] Takeda Development Center Americans, Inc., Cambridge, MA, USA, [11] Ezequiel Dias Foundation, Brazil, [12] Sungkyunkwan University, Suwon, South Korea, [13] Parexel, Stockholm, Sweden, [14]J anssen R&D, Spring House, PA, USA, [15] AstraZeneca, USA, [16]Heva, France, [17] Nelson Mandela University, South Africa, [18] University of Sorocaba, Brazil |
|
Poster Monday, August 25, 2025 Convention Hall |
Poster Session B: Vaccines |
[B-308] Safety Monitoring of Mpox Vaccines in Adults Aged 18-64 Years during the 2022 Mpox Outbreak in the U.S. |
Gruber JF[1], Matuska K[2], Zelaya CE[1], Wang J[1], McMahill-Walraven CN[3], Peetluk L[4], Secora A[5], Krishnakumar S[2], Hu M[2], Amend K[4], Song J[4], Beachler DC[6], Lloyd PC[7], Gwira J[7], Tarazi W[4], Clarke TC[7], Djibo DA[3], Chillarige Y[2], Shoaibi A[1], Anderson S[1], Forshee RA[1] |
[1] FDA, Silver Spring, MD, USA [2] Acumen, Burlingame, CA, USA, [3] CVS Health, Philadelphia, PA, USA [4] Optum, Boston, MA, USA [5] IQVIA, Falls Church, VA, USA, [6] Carelon Research, Wilmington, DE, USA |
|
Poster Monday, August 25, 2025 Convention Hall |
SPOTLIGHT |
[SLB-044] The Relationship between Wildfire Smoke Exposure and Childhood Asthma in California |
Romine J[1], Cullen D[2], White C[3], Deschenes O[3] |
[1] Carelon Research, Wilmington, DE, USA, [2] Elevance Health, Indianapolis, IN, USA, [3] University of California, Santa Barbara, CA, USA |
|
Poster Tuesday, August 26, 2025 Convention Hall |
Poster Session C: Disease Epidemiology / Clinical Course / Other |
[C-019] Rate of Bowel Resection Surgeries among Children with Inflammatory Bowel Disease |
Parlett LE[1], Phillips M[2], Kappelman M[2] |
[1] Carelon Research, Wilmington, DE, USA, [2] University of North Carolina, Chapel Hill, NC, USA |
|
Poster Tuesday, August 26, 2025 Convention Hall |
Poster Session C: Methods in Pharmacoepidemiology / Study Design |
[C-147] Does Health Plan Enrollment Data Support Long-term Follow-up of Patients with Chronic Disease? Assessment of the Healthcare Integrated Research Database (HIRD®) |
Beachler DC[1], Venkataraman M[1], Grabner M[1], Harris KM[1], Willey V[1], Barron JJ[1] |
[1]Carelon Research, Wilmington, DE, USA |
|
Poster Tuesday, August 26, 2025 Convention Hall |
Poster Session C: Methods in Pharmacoepidemiology / Study Design |
[C-160] Using the Potential Outcomes Model to Inform the Design and Interpretation of Causal Studies of the Effectiveness and Safety of Healthcare Interventions: An Interdisciplinary Perspective |
Grabner M[1], Dixon R[1], Hoffman SR[1], Wentz AE[1], Harris K[1], Love SAM[1] |
[1] Carelon Research, Wilmington, DE, USA |
|
Poster Tuesday, August 26, 2025 Convention Hall |
Posters Session C: Methods in Pharmacoepidemiology / Study Design |
[C-179] An Evaluation Strategy to Assess Patient Engagement Quality, Impact, and Outcomes |
Daugherty SE[1], Coleman J[1], Conto R[1], Stephenson JJ[1] |
[1]Carelon Research, Wilmington, DE, USA |
|
Poster Tuesday, August 26, 2025 Convention Hall |
SPOTLIGHT |
[SLC-026] Association between antibiotic exposure and response to treatment of juvenile idiopathic arthritis |
Horton DB[1], Verma C[1], Rege S[1], Iizuka A[1], Iozzio M[1], Koffman D[1], Crystal S[1], Davidow A[2], Gerhard T[1], Parlett LE[3], Rose CD[4], Strom BL[1] |
[1] Rutgers, New Brunswick, NJ, USA, [2] New York University, USA, [3] Carelon Research, Wilmington, DE, USA, [4] Thomas Jefferson University, USA |
